OAHP is delighted to see this great success to a company that works not only in Oxford but increasingly across the UK and beyond. Well done
The Series B investment will enable the Oxford-based company to expand its award-winning artificial intelligence (AI) portfolio into new indications and extend into new high-growth markets
OXFORD, UK, 16th December, 2021 – Brainomix, the AI-powered medtech solutions company, today announces that it has closed a series B financing round, raising £16M ($21.2M) to fund its expansion into new markets and new therapeutic indications, including lung fibrosis and cancer. This investment will build on the proven success of the company’s tech platform in stroke and enable value-generating pharmaceutical partnerships to improve clinical trial success, foster broader adoption of existing therapies in the new indications, and improve patient outcomes.
The financing was co-led by existing investors Boehringer Ingelheim Venture Fund (BIVF) and Parkwalk Advisors, along with new investor, Tencent Holdings, and included participation from Oxford University Innovation Fund (OUIF).
Brainomix has pioneered the development of an AI platform that automates validated imaging biomarkers to improve both diagnosis and treatment decisions. Its e-Stroke platform is the world’s most comprehensive stroke imaging solution and is already widely adopted in multiple healthcare systems worldwide. The platform is the market leader in Europe and has been deployed across the UK as part of a prestigious NHSX AI in Health & Care Award granted in 2020. It is installed in hundreds of hospitals across Europe, US, South America, Asia where it has been clinically proven to drive faster treatment times and improve functional independence for stroke patients.
Read more hereBrainomix Press Release (14-12-21)